Cargando…

Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014

Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to INH may increase the likelihood of negative treatment outcome. Aim: We aimed to determine the impact of INH mono-resistance on TB treatment outcome in the European Union/European Economic Area and to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Karo, Basel, Kohlenberg, Anke, Hollo, Vahur, Duarte, Raquel, Fiebig, Lena, Jackson, Sarah, Kearns, Cathriona, Ködmön, Csaba, Korzeniewska-Kosela, Maria, Papaventsis, Dimitrios, Solovic, Ivan, van Soolingen, Dick, van der Werf, Marieke J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440580/
https://www.ncbi.nlm.nih.gov/pubmed/30914081
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.12.1800392
_version_ 1783407413131476992
author Karo, Basel
Kohlenberg, Anke
Hollo, Vahur
Duarte, Raquel
Fiebig, Lena
Jackson, Sarah
Kearns, Cathriona
Ködmön, Csaba
Korzeniewska-Kosela, Maria
Papaventsis, Dimitrios
Solovic, Ivan
van Soolingen, Dick
van der Werf, Marieke J.
author_facet Karo, Basel
Kohlenberg, Anke
Hollo, Vahur
Duarte, Raquel
Fiebig, Lena
Jackson, Sarah
Kearns, Cathriona
Ködmön, Csaba
Korzeniewska-Kosela, Maria
Papaventsis, Dimitrios
Solovic, Ivan
van Soolingen, Dick
van der Werf, Marieke J.
author_sort Karo, Basel
collection PubMed
description Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to INH may increase the likelihood of negative treatment outcome. Aim: We aimed to determine the impact of INH mono-resistance on TB treatment outcome in the European Union/European Economic Area and to identify risk factors for unsuccessful outcome in cases with INH mono-resistant TB. Methods: In this observational study, we retrospectively analysed TB cases that were diagnosed in 2002–14 and included in the European Surveillance System (TESSy). Multilevel logistic regression models were applied to identify risk factors and correct for clustering of cases within countries. Results: A total of 187,370 susceptible and 7,578 INH mono-resistant TB cases from 24 countries were included in the outcome analysis. Treatment was successful in 74.0% of INH mono-resistant and 77.4% of susceptible TB cases. In the final model, treatment success was lower among INH mono-resistant cases (Odds ratio (OR): 0.7; 95% confidence interval (CI): 0.6–0.9; adjusted absolute difference in treatment success: 5.3%). Among INH mono-resistant TB cases, unsuccessful treatment outcome was associated with age above median (OR: 1.3; 95% CI: 1.2–1.5), male sex (OR: 1.3; 95% CI: 1.1–1.4), positive smear microscopy (OR: 1.3; 95% CI: 1.1–1.4), positive HIV status (OR: 3.3; 95% CI: 1.6–6.5) and a prior TB history (OR: 1.8; 95% CI: 1.5–2.2). Conclusions: This study provides evidence for an association between INH mono-resistance and a lower likelihood of TB treatment success. Increased attention should be paid to timely detection and management of INH mono-resistant TB.
format Online
Article
Text
id pubmed-6440580
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-64405802019-08-08 Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014 Karo, Basel Kohlenberg, Anke Hollo, Vahur Duarte, Raquel Fiebig, Lena Jackson, Sarah Kearns, Cathriona Ködmön, Csaba Korzeniewska-Kosela, Maria Papaventsis, Dimitrios Solovic, Ivan van Soolingen, Dick van der Werf, Marieke J. Euro Surveill Research Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to INH may increase the likelihood of negative treatment outcome. Aim: We aimed to determine the impact of INH mono-resistance on TB treatment outcome in the European Union/European Economic Area and to identify risk factors for unsuccessful outcome in cases with INH mono-resistant TB. Methods: In this observational study, we retrospectively analysed TB cases that were diagnosed in 2002–14 and included in the European Surveillance System (TESSy). Multilevel logistic regression models were applied to identify risk factors and correct for clustering of cases within countries. Results: A total of 187,370 susceptible and 7,578 INH mono-resistant TB cases from 24 countries were included in the outcome analysis. Treatment was successful in 74.0% of INH mono-resistant and 77.4% of susceptible TB cases. In the final model, treatment success was lower among INH mono-resistant cases (Odds ratio (OR): 0.7; 95% confidence interval (CI): 0.6–0.9; adjusted absolute difference in treatment success: 5.3%). Among INH mono-resistant TB cases, unsuccessful treatment outcome was associated with age above median (OR: 1.3; 95% CI: 1.2–1.5), male sex (OR: 1.3; 95% CI: 1.1–1.4), positive smear microscopy (OR: 1.3; 95% CI: 1.1–1.4), positive HIV status (OR: 3.3; 95% CI: 1.6–6.5) and a prior TB history (OR: 1.8; 95% CI: 1.5–2.2). Conclusions: This study provides evidence for an association between INH mono-resistance and a lower likelihood of TB treatment success. Increased attention should be paid to timely detection and management of INH mono-resistant TB. European Centre for Disease Prevention and Control (ECDC) 2019-03-21 /pmc/articles/PMC6440580/ /pubmed/30914081 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.12.1800392 Text en This article is copyright of the authors or their affiliated institutions, 2019. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research
Karo, Basel
Kohlenberg, Anke
Hollo, Vahur
Duarte, Raquel
Fiebig, Lena
Jackson, Sarah
Kearns, Cathriona
Ködmön, Csaba
Korzeniewska-Kosela, Maria
Papaventsis, Dimitrios
Solovic, Ivan
van Soolingen, Dick
van der Werf, Marieke J.
Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014
title Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014
title_full Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014
title_fullStr Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014
title_full_unstemmed Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014
title_short Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014
title_sort isoniazid (inh) mono-resistance and tuberculosis (tb) treatment success: analysis of european surveillance data, 2002 to 2014
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440580/
https://www.ncbi.nlm.nih.gov/pubmed/30914081
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.12.1800392
work_keys_str_mv AT karobasel isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT kohlenberganke isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT hollovahur isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT duarteraquel isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT fiebiglena isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT jacksonsarah isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT kearnscathriona isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT kodmoncsaba isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT korzeniewskakoselamaria isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT papaventsisdimitrios isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT solovicivan isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT vansoolingendick isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014
AT vanderwerfmariekej isoniazidinhmonoresistanceandtuberculosistbtreatmentsuccessanalysisofeuropeansurveillancedata2002to2014